CLINICAL STUDIES
Predictors of cardiogenic shock after thrombolytic therapy for acute myocardial infarction
David Hasdai, MD*,
Robert M. Califf, MD, FACC ,
Trevor D. Thompson, BS ,
Judith S. Hochman, MD, FACC ,
E. Magnus Ohman, MD, FACC ,
Matthias Pfisterer, MD, FACC ,
Eric R. Bates, MD, FACC||,
Alec Vahanian, MD¶,
Paul W. Armstrong, MD, FACC#,
Douglas A. Criger, MPH ,
Eric J. Topol, MD, FACC** and
David R. Holmes, Jr., MD, FACC
* Rabin Medical Center, Petah Tikva, Israel
Duke University Medical Center, Durham, North Carolina, USA
St. Lukes/Roosevelt Hospital Center, New York, New York, USA
University Hospital Basel, Basel, Switzerland
|| University of Michigan Medical Center, Ann Arbor, Michigan, USA
¶ Hospital Tenon, Paris, France
# University of Alberta, Walter C. Mackenzie Health Center, Edmonton, Canada
** The Cleveland Clinic Foundation, Cleveland, Ohio, USA
 Mayo Clinic, Rochester, Minnesota, USA
Manuscript received March 9, 1999;
revised manuscript received July 2, 1999,
accepted September 21, 1999.
Reprint requests and correspondence: Dr. David R. Holmes Jr, Division of Internal Medicine and Cardiovascular Diseases, Mayo Clinic, 200 First Street SW, Rochester, Minnesota 55905
OBJECTIVES
This study characterized clinical factors predictive of cardiogenic shock developing after thrombolytic therapy for acute myocardial infarction (AMI).
BACKGROUND
Cardiogenic shock remains a common and ominous complication of AMI. By identifying patients at risk of developing shock, preventive measures may be implemented to avert its development.
METHODS
We analyzed baseline variables associated with the development of shock after thrombolytic therapy in the Global Utilization of Streptikonase and Tissue-Plasminogen Activator for Occluded Coronary Arteries (GUSTO-I) trial. Using a Cox proportional hazards model, we devised a scoring system predicting the risk of shock. This model was then validated in the Global Use of Strategies to Open Occluded Coronary Arteries (GUSTO-III) cohort.
RESULTS
Shock developed in 1,889 patients a median of 11.6 h after enrollment. The major factors associated with increased adjusted risk of shock were age ( 2 = 285, hazard ratio [95% confidence interval] 1.47 [1.40, 1.53]), systolic blood pressure ( 2 = 280), heart rate ( 2 = 225) and Killip class ( 2 = 161, hazard ratio 1.70 [1.52, 1.90] and 2.95 [2.39, 3.63] for Killip II versus I and Killip III versus I, respectively) upon presentation. Together, these four variables accounted for >85% of the predictive information. These findings were transformed into an algorithm with a validated concordance index of 0.758. Applied to the GUSTO-III cohort, the four variables accounted for >95% of the predictive information, and the validated concordance index was 0.796.
CONCLUSIONS
A scoring system accurately predicts the risk of shock after thrombolytic therapy for AMI based primarily on the patients age and physical examination on presentation.
|
Abbreviations and Acronyms
| | AMI | = acute myocardial infarction | | CI | = confidence interval | | ECG | = electrocardiographic | | GUSTO-I | = Global Utilization of Streptokinase and Tissue-Plasminogen Activator for Occluded Coronary Arteries | | GUSTO-III | = Global Use of Strategies to Open Occluded Coronary Arteries |
|
This article has been cited by other articles:

|
 |

|
 |
 
A. K. Jacobs
Coronary Intervention in 2009: Are Women No Different Than Men?
Circ Cardiovasc Interv,
February 1, 2009;
2(1):
69 - 78.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
H. R. Reynolds, M. E. Farkouh, A. M. Lincoff, A. Hsu, E. Swahn, Z. P. Sadowski, J. A. White, E. J. Topol, J. S. Hochman, and for the GUSTO V Investigators
Impact of Female Sex on Death and Bleeding After Fibrinolytic Treatment of Myocardial Infarction in GUSTO V
Arch Intern Med,
October 22, 2007;
167(19):
2054 - 2060.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
B. Verges, M. Zeller, G. Dentan, J.-C. Beer, Y. Laurent, L. Janin-Manificat, H. Makki, J. E. Wolf, Y. Cottin, and on behalf of the Observatoire des Infarctus de Cot
Impact of Fasting Glycemia on Short-Term Prognosis after Acute Myocardial Infarction
J. Clin. Endocrinol. Metab.,
June 1, 2007;
92(6):
2136 - 2140.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
L. Lorgis, M. Zeller, G. Dentan, P. Sicard, M. Jolak, I. L'Huillier, M. Vincent-Martin, J.C. Beer, H. Makki, P. Gambert, et al.
High levels of N-terminal pro B-type natriuretic peptide are associated with ST resolution failure after reperfusion for acute myocardial infarction
QJM,
April 1, 2007;
100(4):
211 - 216.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
R. H. Mehta, R. M. Califf, J. Garg, H. D. White, F. Van de Werf, P. W. Armstrong, K. S. Pieper, E. J. Topol, and C. B. Granger
The impact of anthropomorphic indices on clinical outcomes in patients with acute ST-elevation myocardial infarction
Eur. Heart J.,
February 2, 2007;
28(4):
415 - 424.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
B. Verges, M. Zeller, J. Desgres, G. Dentan, Y. Laurent, L. Janin-Manificat, I. L'Huillier, G. Rioufol, J.-C. Beer, H. Makki, et al.
High plasma N-terminal pro-brain natriuretic peptide level found in diabetic patients after myocardial infarction is associated with an increased risk of in-hospital mortality and cardiogenic shock
Eur. Heart J.,
September 1, 2005;
26(17):
1734 - 1741.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. Zeller, P. G. Steg, J. Ravisy, Y. Laurent, L. Janin-Manificat, I. L'Huillier, J.-C. Beer, A. Oudot, G. Rioufol, H. Makki, et al.
Prevalence and Impact of Metabolic Syndrome on Hospital Outcomes in Acute Myocardial Infarction
Arch Intern Med,
May 23, 2005;
165(10):
1192 - 1198.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
K. P. Bouki, G. Pavlakis, and E. Papasteriadis
Management of Cardiogenic Shock Due to Acute Coronary Syndromes
Angiology,
March 1, 2005;
56(2):
123 - 130.
[Abstract]
[PDF]
|
 |
|

|
 |

|
 |
 
A. J. Lansky, J. S. Hochman, P. A. Ward, G. S. Mintz, R. Fabunmi, P. B. Berger, G. New, C. L. Grines, C. G. Pietras, M. J. Kern, et al.
Percutaneous Coronary Intervention and Adjunctive Pharmacotherapy in Women: A Statement for Healthcare Professionals From the American Heart Association
Circulation,
February 22, 2005;
111(7):
940 - 953.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
G Montalescot, H R Andersen, D Antoniucci, A Betriu, M J de Boer, L Grip, F J Neumann, and M T Rothman
Recommendations on percutaneous coronary intervention for the reperfusion of acute ST elevation myocardial infarction
Heart,
June 1, 2004;
90(6):
e37 - e37.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
D. R. Holmes Jr
Risk Stratification and Interventional Cardiology: Robert L. Frye Lecture
Mayo Clin. Proc.,
December 1, 2003;
78(12):
1507 - 1518.
[Abstract]
[PDF]
|
 |
|

|
 |

|
 |
 
M. H. Picard, R. Davidoff, L. A. Sleeper, L. A. Mendes, C. R. Thompson, V. Dzavik, R. Steingart, K. Gin, H. D. White, J. S. Hochman, et al.
Echocardiographic Predictors of Survival and Response to Early Revascularization in Cardiogenic Shock
Circulation,
January 21, 2003;
107(2):
279 - 284.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
V. Menon and J. S Hochman
MANAGEMENT OF CARDIOGENIC SHOCK COMPLICATING ACUTE MYOCARDIAL INFARCTION
Heart,
December 1, 2002;
88(5):
531 - 537.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
H.D. White
Cardiogenic shock: a more aggressive approach is now warranted
Eur. Heart J.,
December 1, 2000;
21(23):
1897 - 1901.
[PDF]
|
 |
|

|
 |

|
 |
 
D. Hasdai, R. A. Harrington, J. S. Hochman, R. M. Califf, A. Battler, J. W. Box, M. L. Simoons, J. Deckers, E. J. Topol, and D. R. Holmes Jr.
Platelet glycoprotein IIb/IIIa blockade and outcome of cardiogenic shock complicating acute coronary syndromes without persistent ST-segment elevation
J. Am. Coll. Cardiol.,
September 1, 2000;
36(3):
685 - 692.
[Abstract]
[Full Text]
[PDF]
|
 |
|
|